CSTL - Castle Biosciences, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$47.80
DETAILS
HIGH:
$52.00
LOW:
$40.00
MEDIAN:
$50.00
CONSENSUS:
$47.80
UPSIDE:
137.22%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||
| Revenue | 344.2 | 332.1 | 219.8 | 137.0 | 94.1 | 62.6 | 51.9 | 22.8 | 13.8 |
| Cost of Revenue | 71.0 | 60.2 | 45.0 | 32.0 | 15.8 | 9.7 | 7.3 | 5.3 | 4.9 |
| Gross Profit | 273.2 | 271.9 | 174.8 | 105.0 | 78.3 | 53.0 | 44.6 | 17.5 | 8.8 |
| Operating Expenses | |||||||||
| R&D Expenses | 51.9 | 52.0 | 53.6 | 44.9 | 29.6 | 13.3 | 7.4 | 4.9 | 4.5 |
| SG&A Expenses | 229.3 | 200.0 | 180.2 | 143.0 | 86.7 | 48.1 | 29.8 | 16.5 | 15.3 |
| Other Expenses | 34.8 | 11.1 | 9.0 | (10.0) | 2.0 | (1.9) | 0 | 0 | 0.2 |
| Operating Expenses | 316.0 | 263.2 | 242.8 | 177.9 | 118.3 | 59.5 | 37.2 | 21.3 | 19.7 |
| Operating Income | |||||||||
| Operating Income | (42.8) | 8.7 | (68.0) | (72.9) | (40.1) | (6.5) | 7.3 | (3.8) | (10.9) |
| Interest Expense | 0.1 | 0.6 | 0.0 | 0.0 | 0.0 | 2.6 | 4.6 | 2.3 | 1.6 |
| Interest Income | 11.8 | 12.9 | 10.6 | 4.0 | 0.1 | 0.4 | 0.3 | 0.0 | 0.0 |
| Profitability | |||||||||
| EBITDA | 11.3 | 38.1 | (45.0) | (58.3) | (36.6) | (7.1) | 10.3 | (3.8) | (10.4) |
| EBIT | (29.4) | 22.1 | (57.4) | (68.9) | (40.0) | (7.6) | 9.9 | (4.1) | (10.7) |
| Income Before Tax | (29.5) | 21.6 | (57.4) | (68.9) | (40.0) | (10.2) | 5.3 | (6.4) | (12.4) |
| Income Tax Expense | (5.4) | 3.3 | 0.1 | (1.8) | (8.7) | 0.1 | 0.1 | 0.0 | 0.0 |
| Net Income | (24.2) | 18.2 | (57.5) | (67.1) | (31.3) | (10.3) | 5.3 | (6.4) | (12.4) |
| Per Share Data | |||||||||
| EPS (Basic) | -0.83 | 0.66 | -2.14 | -2.58 | -1.24 | -0.54 | 0.35 | -0.60 | -1.26 |
| EPS (Diluted) | -0.83 | 0.62 | -2.14 | -2.58 | -1.24 | -0.54 | -0.21 | -0.60 | -1.26 |
| Shares Outstanding | 29.0 | 27.8 | 26.8 | 26.1 | 25.1 | 18.9 | 8.6 | 10.7 | 9.8 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Assets | |||||||||
| Cash & Cash Equivalents | 116.7 | 119.7 | 98.8 | 122.9 | 329.6 | 409.9 | 98.8 | 4.5 | 1.2 |
| Short-Term Investments | 182.8 | 173.4 | 144.3 | 135.7 | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 43.4 | 51.2 | 38.3 | 23.5 | 17.3 | 12.8 | 14.6 | 12.1 | 4.7 |
| Inventory | 10.3 | 8.1 | 7.9 | 4.0 | 2.0 | 2.2 | 1.2 | 0.9 | 0.3 |
| Other Current Assets | 8.0 | 7.7 | 6.3 | 6.2 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 361.1 | 360.2 | 295.6 | 292.3 | 353.7 | 429.6 | 116.7 | 18.1 | 6.7 |
| Non-Current Assets | |||||||||
| Property, Plant & Equipment | 112.2 | 62.7 | 37.7 | 26.5 | 16.9 | 7.1 | 2.1 | 1.5 | 1.5 |
| Goodwill | 99.6 | 10.7 | 10.7 | 10.7 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 95.5 | 106.6 | 115.7 | 88.9 | 0 | 0 | 0.0 | 0.0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.5 | 1.6 |
| Other Non-Current Assets | 5.6 | 2.1 | 2.6 | 2.2 | 3.0 | 2.6 | 1.0 | 2.7 | 1.6 |
| Total Non-Current Assets | 217.5 | 171.1 | 157.7 | 155.0 | 108.8 | 9.7 | 3.1 | 4.3 | 3.1 |
| Total Assets | 578.6 | 531.2 | 453.3 | 447.3 | 462.6 | 439.3 | 119.7 | 22.4 | 9.8 |
| Current Liabilities | |||||||||
| Account Payables | 18.7 | 6.9 | 10.3 | 4.7 | 2.5 | 2.1 | 1.9 | 1.5 | 1.1 |
| Short-Term Debt | 1.7 | 0.3 | 0 | 0 | 0 | 0 | 5.8 | 0 | 1 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 6.6 | 0 | 0 | 0.0 |
| Other Current Liabilities | 48.2 | 0.8 | 30.7 | 25.7 | 16.9 | 10.0 | 6.0 | 0.7 | 0 |
| Total Current Liabilities | 68.7 | 49.4 | 47.7 | 36.1 | 24.9 | 20.9 | 15.3 | 6.7 | 5.2 |
| Non-Current Liabilities | |||||||||
| Long-Term Debt | 35.2 | 9.7 | 0 | 0 | 0 | 0 | 19.3 | 24.5 | 17.6 |
| Deferred Tax Liabilities | 2.3 | 1.6 | 0.2 | 0.4 | 0.6 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.5 | 0 | 0 | 0 | 18.3 | 1.0 | 0.1 | 1.2 | 1.3 |
| Total Non-Current Liabilities | 39.0 | 26.0 | 14.4 | 12.1 | 25.9 | 2.8 | 19.3 | 25.7 | 18.9 |
| Total Liabilities | 107.7 | 75.4 | 62.1 | 48.2 | 50.8 | 23.6 | 34.6 | 32.5 | 24.1 |
| Stockholders' Equity | |||||||||
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Retained Earnings | (224.3) | (200.1) | (218.4) | (160.9) | (93.8) | (62.5) | (52.2) | (57.5) | (51.1) |
| Accumulated Other Comprehensive Income | 0.3 | 0.2 | 0.1 | (0.4) | 0 | 0 | 0 | (0.9) | (0.6) |
| Total Stockholders' Equity | 470.9 | 455.8 | 391.3 | 399.1 | 411.7 | 415.7 | 85.1 | (10.1) | (14.3) |
| Total Liabilities & Equity | 578.6 | 531.2 | 453.3 | 447.3 | 462.6 | 439.3 | 119.7 | 22.4 | 9.8 |
| Debt Metrics | |||||||||
| Total Debt | 36.9 | 26.3 | 15.3 | 13.4 | 8.2 | 0 | 25.1 | 24.5 | 18.6 |
| Net Debt | (79.8) | (93.4) | (83.5) | (109.5) | (321.4) | (409.9) | (73.7) | 20.0 | 17.4 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||
| Net Income | (24.2) | 18.2 | (57.5) | (67.1) | (31.3) | (10.3) | 5.3 | (6.4) | (12.4) |
| Depreciation & Amortization | 40.8 | 16.0 | 12.3 | 10.5 | 3.4 | 0.5 | 0.4 | 0.3 | 0.3 |
| Stock-Based Compensation | 45.9 | 50.3 | 51.2 | 36.3 | 21.7 | 8.3 | 1.2 | 0.3 | 0.1 |
| Change in Working Capital | 13.6 | (14.1) | (6.6) | (0.0) | (4.1) | 9.1 | 0.0 | (7.4) | (0.6) |
| Other Non-Cash Items | (5.5) | (7.0) | (4.9) | (19.5) | 0 | 2.2 | 2.4 | 0.5 | 0.5 |
| Operating Cash Flow | 64.3 | 64.9 | (5.6) | (41.7) | (19.0) | 9.9 | 7.0 | (12.3) | (12.2) |
| Investing Activities | |||||||||
| Capital Expenditure | (36.0) | (28.3) | (13.6) | (5.6) | (3.5) | (4.8) | (0.9) | (0.3) | (0.5) |
| Acquisitions | (18.7) | 0.0 | 0 | (27.0) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (188.7) | (205.7) | (189.1) | (134.7) | 0 | 0 | 0 | 0 | 0 |
| Sales/Maturities of Investments | 190.7 | 183.9 | 186.5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (7.6) | 0 | 0.0 | 0.7 | (63.2) | 0.0 | 0 | 0 | 0 |
| Investing Cash Flow | (60.4) | (50.1) | (16.2) | (166.5) | (66.7) | (4.7) | (0.9) | (0.3) | (0.5) |
| Financing Activities | |||||||||
| Net Debt Issuance | (0.1) | 9.9 | (0.1) | (0.1) | (0.0) | (27.4) | 20.9 | 5.4 | 8.6 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (9.1) | (5.8) | (2.2) | 1.6 | 5.4 | 3.2 | 1.4 | 0 | 0.0 |
| Financing Cash Flow | (7.0) | 6.1 | (2.3) | 1.5 | 5.4 | 305.9 | 88.3 | 15.8 | 8.9 |
| Cash Position | |||||||||
| Net Change in Cash | (3.0) | 20.9 | (24.1) | (206.7) | (80.2) | 311.0 | 94.4 | 3.3 | (3.9) |
| Cash at Beginning | 119.7 | 98.8 | 122.9 | 329.6 | 409.9 | 98.8 | 4.5 | 1.2 | 5.1 |
| Cash at End | 116.7 | 119.7 | 98.8 | 122.9 | 329.6 | 409.9 | 98.8 | 4.5 | 1.2 |
| Free Cash Flow | 28.3 | 36.5 | (19.2) | (47.3) | (22.5) | 5.1 | 6.1 | (12.6) | (12.7) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 344.2 | 332.1 | 219.8 | 137.0 | 94.1 | 62.6 | 51.9 | 22.8 | 13.8 |
| Gross Profit | 273.2 | 271.9 | 174.8 | 105.0 | 78.3 | 53.0 | 44.6 | 17.5 | 8.8 |
| Operating Income | (42.8) | 8.7 | (68.0) | (72.9) | (40.1) | (6.5) | 7.3 | (3.8) | (10.9) |
| Net Income | (24.2) | 18.2 | (57.5) | (67.1) | (31.3) | (10.3) | 5.3 | (6.4) | (12.4) |
| EPS (Diluted) | -0.83 | 0.62 | -2.14 | -2.58 | -1.24 | -0.54 | -0.21 | -0.60 | -1.26 |
| Balance Sheet | |||||||||
| Cash & Equivalents | 116.7 | 119.7 | 98.8 | 122.9 | 329.6 | 409.9 | 98.8 | 4.5 | 1.2 |
| Total Assets | 578.6 | 531.2 | 453.3 | 447.3 | 462.6 | 439.3 | 119.7 | 22.4 | 9.8 |
| Total Debt | 36.9 | 26.3 | 15.3 | 13.4 | 8.2 | 0 | 25.1 | 24.5 | 18.6 |
| Stockholders' Equity | 470.9 | 455.8 | 391.3 | 399.1 | 411.7 | 415.7 | 85.1 | (10.1) | (14.3) |
| Cash Flow | |||||||||
| Operating Cash Flow | 64.3 | 64.9 | (5.6) | (41.7) | (19.0) | 9.9 | 7.0 | (12.3) | (12.2) |
| Capital Expenditure | (36.0) | (28.3) | (13.6) | (5.6) | (3.5) | (4.8) | (0.9) | (0.3) | (0.5) |
| Free Cash Flow | 28.3 | 36.5 | (19.2) | (47.3) | (22.5) | 5.1 | 6.1 | (12.6) | (12.7) |